Accepted for/Published in: JMIR Public Health and Surveillance
Date Submitted: Dec 14, 2022
Open Peer Review Period: Dec 14, 2022 - Dec 28, 2022
Date Accepted: Apr 18, 2023
(closed for review but you can still tweet)
Metabolic Dysfunction–associated Fatty Liver Disease can Increase the Risk of Developing Chronic Kidney Disease in Western China: A 14-year Longitudinal Cohort Study
ABSTRACT
Background:
Associations between metabolic dysfunction-associated fatty liver disease (MAFLD) and chronic kidney disease (CKD) is unclear.
Objective:
This long-term cohort study aims to test whether MAFLD is play an important role in the development of CKD.
Methods:
This cohort study included 41,246 participants who had undergone three or more health examinations from 2008 to 2015 in a hospital. Participants were categorized into two groups according to whether they presented with or without MAFLD. The occurrence of new onset CKD was stated as either the eGFR <60 mL/min per 1·73m2 or higher level of albuminuria during their follow-up appointment. The association between MAFLD and CKD has been evaluated by using a Cox regression method.
Results:
The prevalence of MAFLD was found to be 28·8%. Over the course of the 14-year follow-up (median 10.0 years), 5347 (13·0%) participants experienced a new incident of CKD (135·73 per 10000 person-years). MAFLD was discovered as an important risk factor for new incident of CKD (HR 1·18 [95% CI, 1·11-1·26]) by using the multivariable Cox proportional hazard regression model. When stratified by gender, the adjusted HR for the incidence of CKD in male and female patients with MAFLD were respectively 1·16 (95% CI, 1·07-1·26 and 1·32 (95% CI, 1·18-1·48). According to the subgroup analysis results, after adjusting for confounding factors, the MAFLD-related CKD risk was greater in men participants aged <60 years and in those with combined dyslipidemia (P interaction <0.05), but this relationship was not found in women (P interaction >0.05).
Conclusions:
MAFLD play an important role in the development of new incidence of CKD in the long run. Clinical Trial: registered on http://www.chictr.org.cn/index.aspx, registration number was ChiCTR2200058543.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.